This Week At FDA October 2026: Peptide Dispute, Clinical Trial Legislation, Drug Approvals And Medical Device Updates

What the Latest FDA Developments Mean for Pharmaceutical Companies, Biotech Firms, Clinical Trial Sponsors and Medical Device Manufacturers

The U.S. Food and Drug Administration (FDA) continues to shape the regulatory landscape for pharmaceuticals, biologics, clinical research and medical devices. In October 2026, several developments have drawn attention, including a dispute over compounded peptides, proposed legislation to accelerate clinical trials, new drug approvals and updated medical device resources.

The latest FDA report this week highlights regulatory discussions that could influence drug development, patient access, product safety and compliance planning. Key topics include the proposed Faster Clinical Trials Act, research priorities for generic medicines, FDA's approval of a new chronic hepatitis B treatment, and developments involving predetermined change control plans (PCCPs) for medical devices.

For pharmaceutical manufacturers, biotechnology companies, contract research organizations (CROs), clinical investigators and medical device manufacturers, these updates reinforce the importance of monitoring FDA announcements, assessing regulatory implications and maintaining evidence-based compliance strategies.

Important distinction: Proposed legislation, policy discussions and citizen petitions do not automatically create new legal requirements. Companies should monitor official FDA announcements and legislative developments before changing established regulatory procedures.

FDA Peptide Compounding Dispute: Safety, Access and Regulatory Oversight

One of the week's prominent issues concerns the potential compounding of certain peptides that are not approved by FDA as finished drug products.

According to the regulatory news report on October 23, 2026, the Partnership for Safe Medicines filed a citizen petition asking FDA to oppose the compounding of certain peptides, citing concerns about legality and patient safety. Meanwhile, HHS Secretary Robert F. Kennedy Jr. discussed a possible state-regulated marketplace for selected unapproved peptides, and an interim access policy was reportedly submitted for review by the Office of Management and Budget (OMB).

The discussion included six peptides: BPC-157, KPV, TB-500, MOTS-c, Epitenon and Sema. Their possible inclusion in a compounding framework remains a regulatory matter requiring careful assessment.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, qualifying pharmacy compounding is subject to specific statutory conditions. A substance's discussion in a policy proposal or advisory committee recommendation does not, by itself, establish that it can legally be compounded.

What companies should consider

• Monitor official FDA communications and updates concerning bulk drug substances used in compounding.
• Evaluate the applicable legal status of each ingredient and proposed formulation.
• Review product quality, manufacturing controls, sourcing and documentation.
• Avoid presenting an unapproved compounded preparation as an FDA-approved drug.
• Assess the potential impact of future policy changes on product development and distribution.

Faster Clinical Trials Act: Proposed Changes to Clinical Research

Bipartisan legislation introduced by Representatives Jake Auchincloss and Morgan Griffith seeks to simplify clinical trial participation and reduce delays in initiating studies.

The proposed Faster Clinical Trials Act reportedly includes measures to encourage human-based research models, artificial intelligence (AI) and alternatives to animal testing. It also seeks to address common causes of clinical holds and proposes a Center for Clinical Trial Innovation (CCI) within FDA's Center for Drug Evaluation and Research (CDER).

The proposed center would lead a Cures in Care Initiative intended to integrate research into routine healthcare, with the bill calling for at least three trial networks during its first year.

These proposals are particularly relevant to sponsors developing therapies for rare diseases and conditions with limited treatment options. However, the legislation's proposals should not be treated as implemented requirements unless enacted and applicable provisions take effect.

Key FDA Developments briefly

FDA Drug and Biologics Updates

Hibsago approved for chronic hepatitis B

On October 20, 2026, FDA approved GSK's Hibsago (bepirovirsen) injection, in combination with existing antiviral therapy, for certain adults with chronic hepatitis B virus (HBV) infection who do not have cirrhosis and meet the labeled eligibility criteria.

FDA described Hibsago as the first FDA-approved antisense oligonucleotide for chronic hepatitis B. The approval is significant for drug developers exploring novel mechanisms and treatment strategies for chronic viral infections.

The product's prescribing information includes important warnings concerning liver reactions and thrombocytopenia, among other risks. Healthcare professionals must follow the approved labeling, including patient-selection and monitoring requirements.

Jemperli receives accelerated approval for a new use

FDA also granted accelerated approval for a new use of GSK's Jemperli (dostarlimab-gxly) for locally advanced rectal cancer. The treatment may offer an alternative for eligible patients who might otherwise undergo treatment involving chemotherapy, radiation and surgery.

The approval highlights the importance of indication-specific clinical evidence, benefit-risk assessment, labeling review and post-approval obligations associated with accelerated approval.

Generic drug research priorities for FY 2027

FDA's Office of Generic Drugs has identified research priorities that include methods for addressing nitrosamine impurities and improving equivalence approaches for complex active ingredients.

For generic drug manufacturers, these priorities reinforce the need for robust analytical methods, scientifically justified impurity controls, product characterization and appropriate evidence supporting therapeutic equivalence.

Other drug safety and development developments

FDA issued final guidance describing technical specifications for submitting clinical trial data designed to evaluate whether a drug or biological product affects the ability to operate a motor vehicle. Such data may support a marketing application when driving performance is relevant to product safety.

FDA also warned consumers about counterfeit over-the-counter eye drops reported in several U.S. states. Testing of two counterfeit products identified bacterial contamination, underscoring the continuing importance of supply-chain verification and counterfeit medicine controls.

Additionally, CDER published its annual report on the Accelerating Rare disease CURES (ARC) program, covering scientific and regulatory innovation, stakeholder engagement and program operations.

Medical Device Regulatory Updates: PCCPs and Change Management

FDA's Center for Devices and Radiological Health (CDRH) launched a webpage dedicated to predetermined change control plans. PCCPs provide a framework for describing certain planned modifications to a medical device and how those changes will be developed, validated and implemented under an FDA-authorized approach.

PCCPs can be particularly relevant to devices that use AI or machine learning, as well as products that may undergo planned iterative changes. Their suitability depends on the device, submission type and applicable FDA requirements.

Medical device manufacturers should consider the following actions:

• Determine whether the relevant marketing submission can include a PCCP.
• Define the intended scope of planned modifications.
• Establish methods for verification and validation.
• Document change-control procedures and performance monitoring.
• Assess potential impacts on safety, effectiveness and product claims.
• Maintain traceable technical documentation supporting authorized changes.

A PCCP should not be interpreted as blanket permission to make any future device modification. Changes must remain within the authorized plan and applicable regulatory conditions.

Practical FDA Compliance Checklist for 2026

Who Should Monitor These FDA Developments?

Recommended Regulatory Action Plan

Organizations can use a structured approach to translate FDA development into practical compliance activities.

Step 1: Identify relevant updates. Map FDA announcements and proposals to the company's products, development programs and markets.

Step 2: Assess regulatory status. Distinguish final agency actions from proposed legislation, advisory recommendations, petitions and policy discussions.

Step 3: Evaluate potential impact. Determine whether existing studies, manufacturing processes, quality systems, labeling or submission plans require review.

Step 4: Update documentation. Maintain regulatory assessments, risk evaluations, change-control records and supporting technical evidence.

Step 5: Assign ownership. Coordinate regulatory affairs, quality assurance, clinical operations, pharmacovigilance, R&D and medical device teams as appropriate.

Step 6: Monitor implementation. Reassess priorities when FDA issues final guidance, changes a policy, approves a product or announces an applicable deadline.

This approach helps companies avoid premature changes based on proposals while remaining prepared for developments that could affect future regulatory obligations.

Frequently Asked Questions

1. What were the major FDA developments in October 2026?

Key topics included the peptide compounding dispute, the proposed Faster Clinical Trials Act, new drug approvals, generic drug research priorities and FDA's PCCP resources for medical devices.

2. Has FDA approved the six peptides discussed in the compounding debate?

Their discussion in policy proceedings or advisory recommendations does not mean they have been approved as finished drug products. Compounding eligibility must be evaluated separately under the applicable legal framework.

3. Has the Faster Clinical Trials Act become law?

The supplied October 2026 report describes it as proposed legislation. Its status and any subsequent amendments or enactment should be verified through official congressional records.

4. What is Hibsago?

Hibsago (bepirovirsen) is an FDA-approved antisense oligonucleotide used with existing antiviral therapy to treat chronic HBV infection in certain adults without cirrhosis who meet the approved criteria.

5. Why are nitrosamine impurities important for generic drugs?

Nitrosamines may present potential carcinogenic risks depending on the substance and exposure. Manufacturers should evaluate applicable FDA expectations for impurity risk assessment, testing and control.

6. What is a predetermined change control plan?

A PCCP describes specified planned device modifications and methods for developing, validating and implementing them within an authorized regulatory framework.

7. How should companies respond to FDA regulatory updates?

Companies should determine whether each development is final, proposed or advisory; assess applicability; document potential impacts; and update procedures when justified by applicable requirements.

Conclusion

October 2026 FDA regulatory landscape reflects continuing developments in drug safety, pharmaceutical innovation, clinical research and medical device oversight. The peptide compounding debate highlights the importance of legal eligibility and patient safety, while the proposed Faster Clinical Trials Act signals potential interest in reducing research delays and expanding innovative trial approaches.

FDA's approval of Hibsago, its accelerated approval of a new Jemperli indication, generic drug research priorities and PCCP resources also offer important considerations for pharmaceutical and medical device regulatory teams.

For manufacturers, biotech companies, CROs and device developers, the priority is to distinguish confirmed regulatory actions from proposals, assess product-specific implications and maintain effective regulatory intelligence and documentation.

How Maven Regulatory Solutions Can Help

Maven Regulatory Solutions supports organizations seeking to strengthen regulatory readiness across pharmaceutical, biotechnology and medical device development.

We offer support in:

• FDA regulatory strategy and submission planning
• Regulatory intelligence and change-impact assessments
• Clinical trial and clinical data regulatory support
• Pharmaceutical quality and impurity-control assessments
• Medical device regulatory affairs and submission support
• PCCP and product change-control documentation
• Regulatory gap assessments and compliance reviews
• Technical documentation and lifecycle regulatory support

A proactive, evidence-based regulatory strategy can help organizations navigate evolving FDA expectations and support compliant product development and market access.